CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 2,186 enrolled
Drug / intervention
Inguinal swab sample +3 moreprocedure
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03767374
NCT03767374N/ACompleted
CompareCT.gov

Risk-factors for Multidrug-resistant (MDR) and Extensively Drug-resistant (XDR) Bacteria Colonization Among Patients at High Risk of STIs

Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba·observational·Posted Dec 6, 2018·Updated Oct 4, 2024

In Brief

An observational study evaluating Inguinal swab sample, Anal swab sample, and 2 other interventions for Bacterial Infections and HIV Infections. Completed, enrolled 2,186 participants across 1 site.

Detailed Summary

The aim of this study is to identify risk factors and prevalence of multidrug-resistant (MDR) and extensively drug-resistant (XDR) bacteria colonization among patients at high risk of STIs

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsBacterial Infections, HIV Infections
CountriesFrance
CollaboratorsANRS, Emerging Infectious Diseases

Timeline

N/ACompletedFinished
20192020202120222023202420252026
First PostedDec 6, 2018
Enrollment StartMay 11, 2018
Primary CompletionJun 30, 2019
Study CompletionDec 31, 2020
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 7.6 years ago

Interventions

Inguinal swab sampleprocedure

Inguinal samples using swab at cross-sectional visit

Anal swab sampleprocedure

Anal samples using swab at cross-sectional visit and at 6-month visit (for those with ESBL and/or CRE colonization)

Fecal sampleprocedure

Fecal sample at cross-sectional visit and at 6-month visit (for those with ESBL and/or CRE colonization)

Risk factor assessmentother

Patients will be asked questions on risk factors associated with MDR/XDR colonization at cross-sectional visit and at 6-month visit (for those with ESBL and/or CRE colonization